ORMP Oramed Pharmaceuticals Inc. - Common Stock
Oramed Pharmaceuticals Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
और पढ़ें
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
ORMP स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
ORMP स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
लाभांश यील्ड, भुगतान अनुपात, लाभांश इतिहास, 5Y CAGR
| एक्स-डेट | राशि |
|---|---|
| 16 जनवरी 2026 | $0.2500 |
ORMP विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 0 0.0%
- खरीदें 0 0.0%
- होल्ड 3 50.0%
- बेचें 1 16.7%
- मजबूत बिक्री 2 33.3%
12-महीने का मूल्य लक्ष्य
1 विश्लेषक · 2026-08-17Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 31 दिसमबर 2025 | $0.24 | $0.00 | 0.24% |
| 30 सितमबर 2025 | $1.12 | $-0.04 | 1.2% |
| 30 जून 2025 | $0.31 | $-0.04 | 0.35% |
| 31 मार्च 2025 | $-0.19 | $-0.01 | -0.18% |
| 31 दिसमबर 2024 | $0.00 | $-0.03 | 0.03% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| ORMP | $112M | 1.9 | -50.4% | 3202.5% | 37.0% | 0.65% |
| ANTX | $31M | -1.0 | — | — | -57.7% | — |
| SIGA | $438M | 19.1 | -31.8% | 24.6% | 11.4% | — |
| DERM | — | -16.4 | 10.2% | -18.5% | -44.7% | — |
| AARD | $286M | -4.5 | — | — | -47.3% | — |
| LENZ | $502M | -5.6 | — | -430.2% | -33.5% | — |
| NRXP | — | — | — | — | — | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Cost of Revenue | $2M | · | · | · | · | · | $90.0K | $-86.0K | $187.0K | |
| Gross Profit | $13.0K | · | · | · | · | · | · | · | · | |
| R&D Expense | $6M | $6M | $9M | $28M | · | $10M | $14M | $12M | $10M | |
| SG&A Expense | $9M | $6M | $8M | $14M | · | $4M | $4M | $4M | $3M | |
| Operating Income | $-15M | $-13M | $-16M | $-41M | · | $-12M | $-15M | $-14M | $-11M | |
| Interest Expense | · | · | $2M | · | · | · | · | · | · | |
| Interest Income | · | · | $10.0K | · | · | · | · | · | · | |
| Other Non-op | $-606.0K | $-27.0K | $13.3K | $3M | · | · | · | · | · | |
| Pretax Income | $75M | $-16M | $5M | $-38M | · | $-12M | $-14M | $-13M | $-10M | |
| Income Tax | $11M | $3M | · | $100.0K | · | · | $300.0K | · | $400.0K | |
| Net Income | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| EPS (Basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| EPS (Diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| Shares (Basic) | 41,402,997 | 40,850,446 | 40,315,068 | 38,997,649 | · | · | · | · | · | |
| Shares (Diluted) | 42,418,644 | 40,850,446 | 40,566,901 | 38,997,649 | · | · | · | · | · | |
| EBITDA | $-15M | · | $-16M | $-41M | · | $-12M | $-15M | · | · |
बैलेंस शीट 23
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $54M | $9M | $40M | · | $19M | $3M | $5M | $4M | |
| Short-term Investments | $5M | $3M | · | · | $8M | $3M | · | $5M | · | |
| Prepaid Expense | $3M | $1M | $537.0K | $1M | · | $611.0K | $1M | $574.0K | · | |
| Current Assets | $133M | $143M | $163M | $157M | $148M | $41M | $33M | $31M | · | |
| PP&E (Net) | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | · | |
| Other Non-current Assets | $44.0K | $32.0K | $27.0K | · | · | · | · | · | · | |
| Total Assets | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Accounts Payable | $443.0K | $789.0K | $551.0K | $4M | $5M | $2M | $3M | $2M | · | |
| Accrued Liabilities | $1M | $402.0K | $605.0K | · | · | · | · | · | · | |
| Short-term Debt | $652.0K | $329.0K | $51M | · | · | · | $3M | $2M | · | |
| Current Liabilities | $19M | $6M | $53M | $6M | $7M | $5M | $5M | $5M | · | |
| Capital Leases | $540.0K | $156.0K | $342.0K | $647.0K | $370.0K | $31.0K | · | · | · | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | $60.0K | $63.0K | · | · | $211.0K | $271.0K | $313.0K | · | |
| Long-term Debt | · | · | · | $25.0K | $12M | · | $10M | $11M | · | |
| Total Debt | · | · | $51M | · | · | · | $3M | · | · | |
| Common Stock | $472.0K | $480.0K | $485.0K | $476.0K | $459.0K | $284.0K | $208.0K | $207.0K | · | |
| Paid-in Capital | · | · | · | $314M | $293M | $125M | · | · | · | |
| Retained Earnings | $-123M | $-177M | $-158M | $-163M | $-127M | $-93M | $-81M | $-69M | · | |
| AOCI | · | · | · | · | · | · | · | $702.0K | · | |
| Stockholders' Equity | $200M | $145M | $164M | $152M | $166M | $33M | $19M | $31M | $19M | |
| Liabilities + Equity | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Shares Outstanding | 39,275,006 | 39,920 | 40,339,000 | 39,564,000 | 38,158 | 23,675,530 | 17,383,359 | 17,369,875 | · |
नकदी प्रवाह 12
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | $4M | $12M | · | $465.0K | $808.0K | $2M | $2M | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-8M | $-10M | $-28M | · | $-12M | $-13M | $-15M | $-6M | |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | · | $82.0K | $15.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $5M | $106M | $-73M | $30M | · | $5M | $11M | $-7M | $4M | |
| Stock Issued | · | · | $2M | $12M | · | · | · | · | · | |
| Stock Repurchased | $5M | $2M | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | $2M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-5M | $-52M | $52M | $11M | · | $24M | · | $23M | $2M | |
| Net Change in Cash | $-8M | $45M | $-31M | $13M | · | $16M | $-2M | $1M | $62.0K | |
| Taxes Paid | · | $2M | · | $2M | · | · | $300.0K | · | $400.0K | |
| Free Cash Flow | $-9M | · | $-11M | $-28M | · | $-13M | $-13M | · | · |
लाभप्रदता 8
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | · | · | · | · | · | |
| Operating Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| Net Margin | 3202.5% | · | 412.3% | -1397.1% | · | -424.8% | -531.1% | · | · | |
| Pretax Margin | 3766.2% | · | 379.7% | · | · | -424.8% | -520.0% | · | · | |
| EBITDA Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| ROA | 33.2% | · | 2.9% | -22.2% | · | -29.0% | -35.0% | · | · | |
| ROE | 37.0% | · | 3.5% | -23.7% | · | -47.0% | -70.1% | · | · | |
| ROIC | -6.4% | · | · | · | · | · | -67.6% | · | · |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · | 8.9 | 6.3 | · | · | |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · | 5.0 | 1.3 | · | · | |
| Debt / Equity | · | · | 0.3 | · | · | · | 0.1 | · | · | |
| Interest Coverage | · | · | -7.7 | · | · | · | · | · | · |
दक्षता 1
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | · | 0.1 | 0.1 | · | · |
विकास दरें 2
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -50.4% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $3M | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Net Income TTM | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| Market Cap | $112M | · | $93M | $476M | · | $83M | $58M | · | · | |
| Enterprise Value | · | · | $77M | · | · | · | $53M | · | · | |
| P/E | 1.9 | -5.0 | 16.5 | -12.8 | · | · | · | · | · | |
| P/S | 56.0 | · | 69.5 | 176.1 | · | 30.5 | 21.4 | · | · | |
| P/B | 0.6 | · | 0.6 | 3.1 | · | 2.5 | 3.0 | · | · | |
| P / Tangible Book | 0.6 | 0.7 | 0.6 | 3.1 | · | 2.5 | · | · | · | |
| P / Cash Flow | -12.2 | · | -9.1 | -17.0 | · | -6.6 | -4.5 | · | · | |
| P / FCF | -12.2 | · | -8.8 | -16.8 | · | -6.6 | -4.5 | · | · | |
| EV / EBITDA | · | · | -4.9 | · | · | · | -3.6 | · | · | |
| EV / FCF | · | · | -7.3 | · | · | · | -4.1 | · | · | |
| EV / Revenue | · | · | 57.8 | · | · | · | 19.8 | · | · | |
| Earnings Yield | 52.6% | -19.8% | 6.1% | -7.8% | · | · | · | · | · |
आय विवरण 17
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | · | · | $2M | · | · | · | · | $0 | · | $674.0K | $666.0K | $681.0K | $682.0K | |
| Cost of Revenue | · | · | $0 | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Gross Profit | · | · | $0 | · | · | $13.0K | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | · | $2M | $2M | $1M | $1M | $2M | $1M | $2M | $1M | $1M | $2M | $957.0K | $2M | $4M | $7M | $5M | |
| SG&A Expense | $3M | $2M | $4M | $1M | $1M | $2M | $2M | $847.0K | $2M | $2M | $2M | $3M | $2M | $1M | $3M | $3M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $11.0K | |
| Operating Income | $-3M | $-4M | $-6M | $-2M | $-2M | $-4M | $-4M | $-3M | $-3M | $-3M | $-4M | $-3M | $-4M | $-5M | $-10M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $592.0K | · | $826.0K | · | · | · | · | |
| Other Non-op | $-4.0K | $-100.0K | $-74M | $61M | · | $-143.0K | $-2M | $-15M | $14M | $4M | $-4M | $435.0K | $2M | $2M | $1M | $1M | |
| Pretax Income | $102M | $49M | $10M | $59M | $13M | $-7M | $-10M | $-19M | $11M | $2M | $13M | $-3M | $-1M | · | $-9M | $-7M | |
| Income Tax | $23M | $11M | $-212.0K | $11M | $-126.0K | $584.0K | $416.0K | $1M | $2M | · | · | · | · | · | $0 | $100.0K | |
| Net Income | $78M | $38M | $10M | $48M | $13M | $-8M | $-10M | $-20M | $9M | $2M | $13M | $-3M | $-1M | $-3M | $-8M | $-7M | |
| EPS (Basic) | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| EPS (Diluted) | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| Shares (Basic) | 41,040,479 | 40,773,866 | -83,325,572 | 41,756,301 | 41,743,486 | 41,228,782 | -81,842,111 | 40,896,845 | 40,959,759 | 40,835,953 | -80,397,680 | 40,445,896 | 40,225,594 | 40,041,258 | -77,577,522 | 39,100,231 | |
| Shares (Diluted) | 42,501,252 | 41,970,186 | -84,194,067 | 42,774,504 | 42,609,425 | 41,228,782 | -83,201,413 | 40,896,845 | 41,591,007 | 41,564,007 | -80,145,847 | 40,445,896 | 40,225,594 | 40,041,258 | -77,577,522 | 39,100,231 | |
| EBITDA | $-3M | $-4M | · | $-2M | $-2M | $-4M | · | $-3M | $-3M | $-3M | · | $-3M | $-4M | $-5M | · | $-8M |
बैलेंस शीट 22
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $13M | $46M | $52M | $16M | · | $54M | · | $10M | $19M | · | · | · | · | $40M | · | |
| Short-term Investments | $846.0K | $5M | $5M | $5M | $2M | $4M | $3M | $57M | $66M | $78M | · | $49.4K | $943.0K | $2M | · | $5M | |
| Prepaid Expense | $2M | $2M | $3M | $1M | $1M | $832.0K | $1M | $474.0K | $533.0K | $501.0K | $537.0K | $666.0K | $769.0K | · | $1M | · | |
| Current Assets | $53M | $68M | $133M | $136M | $99M | $131M | $143M | $143M | $153M | $177M | $163M | $176M | $151M | $155M | $157M | $160M | |
| PP&E (Net) | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K | $765.0K | $819.0K | $873.0K | $923.0K | $945.0K | $977.0K | $815.0K | $535.0K | |
| Other Non-current Assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | · | · | · | $27.0K | · | · | · | · | · | |
| Total Assets | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Accounts Payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | $5M | $3M | $1M | $551.0K | $3M | $828.0K | $4M | $4M | $4M | |
| Accrued Liabilities | $1M | $1M | $1M | $585.0K | $841.0K | $800.0K | $402.0K | · | · | · | $605.0K | · | · | · | · | · | |
| Short-term Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | $51M | $75M | $3.0K | $1.0K | · | · | |
| Current Liabilities | $11M | $11M | $19M | $6M | $4M | $5M | $6M | $5M | $4M | $34M | $53M | $78M | $1M | $5M | $6M | $7M | |
| Capital Leases | $484.0K | $493.0K | $540.0K | $589.0K | $648.0K | $120.0K | $156.0K | $186.0K | $236.0K | $272.0K | $342.0K | $389.0K | $488.0K | $564.0K | $647.0K | $672.0K | |
| Deferred Tax | $40M | $18M | $8M | $8M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $60.0K | $60.0K | $60.0K | · | $63.0K | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $75M | · | · | · | $5M | |
| Total Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | · | $75M | $3.0K | $1.0K | · | · | |
| Common Stock | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K | $488.0K | $487.0K | $485.0K | $484.0K | $484.0K | $481.0K | $476.0K | $470.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | $319M | $317M | · | $308M | |
| Retained Earnings | $-7M | $-85M | $-123M | $-123M | $-171M | $-184M | $-177M | $-166M | $-147M | $-156M | $-158M | $-171M | $-168M | $-166M | $-163M | $-155M | |
| Stockholders' Equity | $317M | $238M | $200M | $203M | $155M | $141M | $146M | $156M | $177M | $167M | $164M | $149M | $152M | $151M | $152M | $154M | |
| Liabilities + Equity | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Shares Outstanding | 41,314,211 | 40,926,081 | 39,275,006 | 40,838,226 | 40,845,087 | 40,850,455 | 39,919,545 | 40,209,575 | 40,628,924 | 40,519,160 | 40,338,979 | 40,282,688 | 40,219,396 | 39,969,979 | 39,563,888 | 39,113,236 |
नकदी प्रवाह 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $2M | $719.0K | $800.0K | $2M | $1M | $301.0K | $1M | $1M | $1M | $852.0K | $2M | $173.0K | $3M | $3M | |
| Deferred Tax | $22M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-200.0K | $-3M | $-466.0K | $-2M | $-4M | $-4M | $-2M | $-7M | $2M | $-1M | $-1M | $-694.0K | $-3M | $-6M | $-8M | $-2M | |
| CapEx | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K | $20.0K | $199.0K | $308.0K | $121.0K | |
| Investing Cash Flow | $4M | $-19M | $-2M | $38M | $-55M | $24M | $15M | $-34M | $95M | $30M | $30M | $-75M | $-15M | $-13M | $11M | $1M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-2.0K | $0 | $2M | $4M | $-3M | |
| Stock Repurchased | · | · | $4M | $361.0K | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | $78.0K | $10M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-2M | $-10M | $-4M | $-361.0K | · | · | $-1M | $-1M | $-31M | $-19M | $-25M | $75M | $0 | $2M | $4M | $4M | |
| Net Change in Cash | $2M | $-33M | $-6M | $36M | $-59M | $20M | $12M | $-43M | $66M | $10M | $4M | $-1M | $-17M | $-16M | $7M | $3M | |
| Taxes Paid | · | · | · | $-7M | · | · | · | · | · | · | · | $527.0K | $3M | $308.0K | · | $167.0K | |
| Free Cash Flow | · | $-3M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-6M | · | · |
लाभप्रदता 8
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 0.65% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| Net Margin | · | · | · | · | · | -382.1% | · | · | · | · | · | · | -177.2% | -542.2% | · | -1063.5% | |
| Pretax Margin | · | · | · | · | · | -352.9% | · | · | · | · | · | · | · | · | · | -1048.8% | |
| EBITDA Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| ROA | 29.4% | 18.4% | · | 25.1% | 7.7% | -4.3% | · | -9.9% | 5.4% | 0.85% | · | -1.6% | -0.75% | -2.2% | · | -5.9% | |
| ROE | 33.1% | 20.2% | · | 26.9% | 8.0% | -5.0% | · | -12.8% | 5.6% | 0.97% | · | -2.1% | -0.78% | -2.3% | · | -6.5% | |
| ROIC | -0.67% | -1.2% | · | -0.97% | -1.6% | -3.5% | · | -2.1% | -1.5% | · | · | · | · | · | · | -5.4% |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 6.5 | · | 22.2 | 26.8 | 23.9 | · | 27.1 | 41.1 | 5.3 | · | 2.2 | 141.5 | 31.2 | · | 24.5 | |
| Quick Ratio | 1.5 | 1.7 | · | 9.3 | 4.8 | 0.7 | · | 10.9 | 20.4 | 2.9 | · | 0.0 | 0.9 | 0.5 | · | 0.8 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.2 | · | 0.5 | 0.0 | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -5.0 | · | -3.5 | · | · | · | · |
दक्षता 1
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 |
मूल्यांकन (TTM) 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Net Income TTM | $178M | $92M | · | $34M | $-5M | $-17M | · | $-12M | $6M | $-6M | · | $-15M | $-22M | $-32M | · | $-36M | |
| Market Cap | $199M | $139M | · | $108M | $92M | $87M | · | $98M | $104M | $118M | · | $105M | $144M | $87M | · | $253M | |
| Enterprise Value | · | · | · | $51M | $74M | · | · | · | · | $54M | · | · | · | · | · | · | |
| P/E | 1.1 | 1.6 | · | 3.4 | -16.1 | -5.2 | · | -8.1 | 17.1 | -19.5 | · | -261.0 | 10.5 | 3.4 | · | 7.0 | |
| P/S | · | · | · | · | · | · | · | 36.4 | 38.7 | 43.9 | · | 39.0 | 53.4 | 32.4 | · | 94.0 | |
| P/B | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Tangible Book | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Cash Flow | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.2 | · | · | · | -15.7 | · | · | |
| P / FCF | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.1 | · | · | · | -15.2 | · | · | |
| EV / EBITDA | · | · | · | -20.9 | -29.9 | · | · | · | · | -18.2 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -36.6 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | 20.0 | · | · | · | · | · | · | |
| Earnings Yield | 87.1% | 63.5% | · | 29.2% | -6.2% | -19.2% | · | -12.3% | 5.8% | -5.1% | · | -0.38% | 9.5% | 29.4% | · | 14.3% | |
| Payout Ratio | · | 27.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $2M | — | $1M | $3M | — |
| सकल मार्जिन % | 0.65% | — | — | — | — |
| परिचालन मार्जिन % | -754.4% | — | -1176.8% | -1502.0% | — |
| शुद्ध आय | $64M | $-19M | $5M | $-37M | — |
| तनुकरणित EPS | $1.50 | $-0.48 | $0.14 | $-0.94 | — |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | — | — | 0.3 | — | — |
| वर्तमान अनुपात | 7.0 | — | 3.1 | 27.3 | — |
| त्वरित अनुपात | 2.7 | — | 1.3 | 0.7 | — |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-9M | — | $-11M | $-28M | — |
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 88 फाइलर्स · $64.4M कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 30 (+13 पिछली तिमाही की तुलना में) | 8 (0 पिछली तिमाही की तुलना में) | 19 (-1 पिछली तिमाही की तुलना में) | 19 (+5 पिछली तिमाही की तुलना में) | -209K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
कंपनी के अंदरूनी सूत्र 30 इनसाइडर्स · 13 अधिकारी · 16 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO | 30 मार्च 2026 F | 3422243 | 0 | 0 | $0 |
| Avraham Gabay | Chief Financial Officer | 1 जुलाई 2026 S | 671785 | 0 | 1 | $-330854 |
| David Silberman | Chief Financial Officer | 4 जनवरी 2024 A | 366500 | 0 | 0 | $0 |
| Hilla Eisenberg | CFO, Treasurer and Secretary | 26 फ़रवरी 2019 A | — | 0 | 0 | $0 |
| Yifat Hen Zommer | CFO, Treasurer and Secretary | 30 जून 2017 A | 46560 | 0 | 0 | $0 |
| Chaime Orlev | CFO, Treasurer and Secretary | 12 अक्टूबर 2008 A | — | 0 | 0 | $0 |
| Joshua Hexter | COO & CBO | 2 जुलाई 2026 M | 1073384 | 0 | 1 | $-611020 |
| Miriam Kidron | Chief Scientific Officer | 30 मार्च 2026 F | 1133138 | 0 | 0 | $0 |
| Netanel Derovan | Chief Legal Officer | 26 मई 2023 A | 149500 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3 जनवरी 2023 S | 126143 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3 जनवरी 2022 A | 109468 | 0 | 0 | $0 |
| Mark Daniel Hasleton | VP Business Development | 26 फ़रवरी 2019 A | — | 0 | 0 | $0 |
| Ronald Edward Law | Chief Strategy Officer | 20 मार्च 2017 A | — | 0 | 0 | $0 |
| Yehuda Reznick | निदेशक | 31 दिसमबर 2025 A | 105180 | 0 | 0 | $0 |
| Daniel Aghion | निदेशक | 31 दिसमबर 2025 A | 113441 | 0 | 0 | $0 |
| Benjamin Shapiro | निदेशक | 31 दिसमबर 2025 A | 123220 | 0 | 0 | $0 |
| Arie Mayer | निदेशक | 31 दिसमबर 2025 A | 168009 | 0 | 0 | $0 |
| Leonard Sank | निदेशक | 5 जून 2025 A | 134531 | 0 | 0 | $0 |
| Yadin Rozov | निदेशक | 4 जनवरी 2024 A | 155320 | 0 | 0 | $0 |
| Kevin Rakin | निदेशक | 21 मार्च 2022 S | 46661 | 0 | 0 | $0 |
| Aviad Friedman | निदेशक | 3 जनवरी 2022 G | 0 | 0 | 0 | $0 |
| Gao Xiaoming | निदेशक | 8 जनवरी 2020 A | — | 0 | 0 | $0 |
| David Mark Slager | निदेशक | 15 अप्रैल 2019 A | 1316328 | 0 | 0 | $0 |
| Xiaopeng Li | निदेशक | 2 अगस्त 2017 P | 206350 | 0 | 0 | $0 |
| Harold Jacob | निदेशक | 10 मार्च 2016 S | 16396 | 0 | 0 | $0 |
| Michael Berelowitz | निदेशक | 9 दिसमबर 2015 S | 22896 | 0 | 0 | $0 |
| Gerald M Ostrov | निदेशक | 23 फ़रवरी 2015 A | 24896 | 0 | 0 | $0 |
| REGALS CAPITAL MANAGEMENT LP | 10% मालिक | 23 दिसमबर 2015 X | 1186823 | 0 | 0 | $0 |
| Zeev Bronfeld | 10% मालिक | 27 सितमबर 2011 S | 5808517 | 0 | 0 | $0 |
| Michael Young | — | 27 मई 2004 S | 0 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 9 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 22 जुलाई 2026 | 3.30% | संशोधन | — | SEC |
| Nadav Kidron ×8 फाइलिंग | 28 अगस्त 2025 | 7.60% | संशोधन | — | SEC |
| Regals Capital Management LP, Regals Fund LP, David M. Slager ×2 फाइलिंग | 20 जुलाई 2018 | — | प्रारंभिक फाइलिंग | — | SEC |
| Hefei Tianhui Incubator of Technologies Co., Ltd | 6 जनवरी 2016 | — | प्रारंभिक फाइलिंग | — | SEC |
| Leonard Sank | 15 दिसमबर 2014 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| Miriam Kidron ×2 फाइलिंग | 3 फ़रवरी 2014 | — | प्रारंभिक फाइलिंग | — | SEC |
| Zeev Bronfeld | 6 मार्च 2006 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 10 जून 2004 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 10 जून 2004 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 14 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| IWC · iShares Trust | 0.03% | 114970 SH | 8 अगस्त 2026 | दैनिक |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.01% | 7046 SH | 8 अगस्त 2026 | दैनिक |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 29637 SH | 8 अगस्त 2026 | दैनिक |
| IWN · iShares Trust | 0.01% | 315439 SH | 8 अगस्त 2026 | दैनिक |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 28155 NS | 31 मई 2026 | N-PORT |
| IWM · iShares Trust | 0.00% | 621705 SH | 8 अगस्त 2026 | दैनिक |
| DFAS · Dimensional ETF Trust | 0.00% | 26896 NS | 30 अप्रैल 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 4523 NS | 30 अप्रैल 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 36536 NS | 30 अप्रैल 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.00% | 4152 NS | 31 मई 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 3431 NS | 30 अप्रैल 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.00% | 196765 SH | 8 अगस्त 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3480 SH | 8 अगस्त 2026 | दैनिक |
| DXUV · Dimensional ETF Trust | 0.00% | 4 NS | 30 अप्रैल 2026 | N-PORT |